Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abramson Cancer Center at Penn Medicine
This trial is a randomized Phase II study of FOLFIRINOX versus gemcitabine/abraxane in patients with completely resected pancreatic cancer (Stages I-III). Patients will receive eight weeks of chemotherapy, then 5-FU/radiation, then another 8 weeks.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have histologically or cytologically confirmed evidence of pancreatic carcinoma.
You may not be if
Patients must have had no prior chemotherapy or radiation therapy for pancreatic cancer.
Age \> 18 years.
Patient must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Patients must have normal organ and marrow function measured within 2 weeks, prior to registration as follows:
Absolute Neutrophil Count (ANC) \> 1,500/µL Platelets \> 100,000/µL Total bilirubin less than 2-fold upper limit of normal (ULN) Aspartate Aminotransferase (AST)/alanine aminotransferase (ALT)\<2.5X institutional upper limit of normal Creatinine clearance \> 60mL/min for patients with creatinine levels above institutional normal.
Patients must be \> 4 weeks and \< 12 weeks post-surgery at time of study registration.
Women of childbearing potential and sexually active males are strongly advised to use appropriate contraceptive measures.
Women must not be pregnant or breast-feeding.
Patients receiving any other investigational agents.